SHANGHAI, Oct. 14, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) in China to initiate clinical study in patients with advanced solid tumors. 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly optimized structure integrates three key elements: - Mab0727: A highly specific CDH17 monoclonal antibody with rapid int
Multiple Iridium data services integrated into the powerful Snapdragon platform for U.S. government and allied users MCLEAN, Va., Oct. 14, 2025 -- Iridium Communications Inc. (NASDAQ: IRDM), a leading provider of global voice, data, and PNT satellite services, and Qualcomm Technologies, Inc. (QTI) today announced that they have successfully integrated Iridium® data services into the Snapdragon® Mission Tactical Radio (MTR) and intend to make these services available for adoption and use by U.S. government customers and approved allied partners. By integra
-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed -- -- Interim analysis from RSV re-vaccination trial demonstrates ≥60% higher trend in RSV neutralizing antibodies for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) i
Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that it has been awarded a £1.2 billion, 15-year contract by the NHS Business Services Authority (NHSBSA) to deliver the Future NHS Workforce Solution. Infosys will develop a cutting-edge, data-driven workforce management solution that will replace the current Electronic Sta
[ 메디채널 김갑성 기자 ] - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne
[ 메디채널 김갑성 기자 ] —— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing, Zhejiang, gathering leading experts including academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, together with international figures such as U.S. National Academy of Engineering member Leonard Pinchuk, UK Royal Society Fellow Molly Stevens, and Professor Kunio Ishikawa, President of the Japanese Society for Biomaterials.&
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise. Q3 2025 Highlights Q3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year. FY 2025 revenue guidance increased to $800 million to $820 million[1]. Gozellix® now fully reimbursed by Centers for Medicare and Medicaid Services
TAIPEI, Oct. 14, 2025 -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, which is held in Berlin, Germany, from Oct 17 to 21, 2025. Abstract: 2242Title: Preclinical development of GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor, while combined with GNTbm-38 showing potent induced tumor microenvironment remodeling activity in cancer immunotherapySession Date/Tim
In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. Telitacicept met the primary endpoint and all key secondary endpoints. Patients in Telitacicept groups showed significant improvement in disease activity compared to the placebo group. Approximately 71.8% of patients receiving Telitacicept 160mg achieved an ESSDAI reduction of ≥3 points at 24 w
SHANGHAI, Oct. 14, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. This marks an important clinical achievement following EVM14's Investigational New Drug (IND) approvals by both the U.S. Food and Drug Adminis